|
1
|
Katsura F, Eura M, Chikamatsu K, Oiso M,
Yumoto E and Ishikawa T: Analysis of individual specific cytotoxic
T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
Jpn J Clin Oncol. 30:117–121. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boel P, Wildmann C, Sensi ML, Brasseur R,
Renauld JC, Coulie P, Boon T and van der Bruggen P: BAGE: a new
gene encoding an antigen recognized on human melanomas by cytolytic
T lymphocytes. Immunity. 2:167–175. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Renkvist N, Castelli C, Robbins PF and
Parmiani G: A listing of human tumor antigens recognized by T
cells. Cancer Immunol Immunother. 50:3–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang
XW, QU P and Zhang XM: The cloning of tumor-associated gene MAGE in
human hepatocellular carcinoma cell line. Chin J Cell Mol Immunol.
18:270–274. 2002.
|
|
5
|
Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY
and Sun ZT: Association of HLA-A02 genotype with hepatocellular
carcinoma in a prevalent area of China. Chin J Immunol. 15:305–310.
1999.
|
|
6
|
Cai SL, Zhao HT, Leng XS, Cheng TH, Gong
SY, Peng JR, Cong X, Wang Y, Rui JA, Hui YZ, Du RY and Chen WF:
Melanoma antigen-3 expression in human hepatocellular carcinoma.
Chin J Surg. 38:693–696. 2000.PubMed/NCBI
|
|
7
|
Pascolo S, Schirle M, Guckel B, Dumrese T,
Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG and
Stevanovic S: A MAGE-A1 HLA-A*0201 epitope identified by mass
spectrometry. Cancer Res. 61:4027–4077. 2001.
|
|
8
|
Vander Bruggen P, Bastin J and Boon T,
Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A
and Boon T: A peptide encoded by human gene MAGE-3 and presented by
HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells
expressing MAGE-3. Eur J Immunol. 24:3038–3043. 1994.
|
|
9
|
Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu
W, Lu SY, Chen GS and Sui YF: Identification of HLA-A2-restricted
CTL epitope encoded by the MAGE-n gene of human hepatocellular
carcinoma. Cancer Biol Ther. 3:891–898. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marchand M, van Baren N, Weynants P, et
al: Tumor regression observed in patients with metastic melanoma
treated with an antigenic peptide encoded by gene MAGE-3 and
presented by HLA-A1. Int J Cancer. 80:219–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horiguchi Y, Nukaya I, Okazawa K,
Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K and Murai M:
Screening of HLA-A24-restricted epitope peptides from
prostate-specific membrane antigen that induce specific antitumor
cytotoxic T lymphocytes. Clin Cancer Res. 8:3885–3892. 2002.
|
|
12
|
Feuerer M, Beckhove P, Bai L, Solomayer
EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V
and Umansky V: Therapy of human tumors in NOD/SCID mice with
patient-derived reactivated memory T cells from bone marrow. Nat
Med. 7:452–458. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dagher R, Long LM, Read EJ, Leitman SF,
Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ
and Mackall CL: Pilot trial of tumor-specific peptide vaccination
and continuous infusion interleukin-2 in patients with recurrent
Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH
study. Med Pediatr Oncol. 38:158–164. 2002. View Article : Google Scholar
|
|
14
|
Schiavetti F, Thonnard J, Colau D, Boon T
and Coulie PG: A human endogenous retroviral sequence encoding an
antigen recognized on melanoma by cytolytic T lymphocytes. Cancer
Res. 62:5510–5516. 2002.PubMed/NCBI
|
|
15
|
Schirle M, Keilholz W, Weber B,
Gouttefangeas C, Dumrese T, Becker HD, Stevanović S and Rammensee
HG: Identification of tumor-associated MHC class I ligands by a
novel T cell-independent approach. Eur J Immunol. 30:2216–2225.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XM, Zhang YF, Huang Y, Qu P, Ma B,
Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ and Sui YF: The anti-tumor
immune response induced by a combination of MAGE-3/MAGE-n-derived
peptides. Oncol Rep. 20:245–252. 2008.PubMed/NCBI
|
|
17
|
Sidney J, Grey HM, Kubo RT and Sette A:
Practical, biochemical and evolutionary implications of the
discovery of HLA class I supermotifs. Immunol Today. 17:261–266.
1996. View Article : Google Scholar : PubMed/NCBI
|
